2.35 USD
+0.12 (+5.38%)
2.37 USD
+0.02 (+0.85%)
CATX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. The financial health of CATX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CATX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CATX had negative earnings in the past year.
CATX had a negative operating cash flow in the past year.
CATX had negative earnings in each of the past 5 years.
CATX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -30.56%, CATX is doing good in the industry, outperforming 67.23% of the companies in the same industry.
The Return On Equity of CATX (-35.74%) is better than 73.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.56% | ||
| ROE | -35.74% | ||
| ROIC | N/A |
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CATX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CATX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CATX has more shares outstanding
CATX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CATX has an improved debt to assets ratio.
2.2 Solvency
CATX has an Altman-Z score of 0.91. This is a bad value and indicates that CATX is not financially healthy and even has some risk of bankruptcy.
CATX's Altman-Z score of 0.91 is fine compared to the rest of the industry. CATX outperforms 62.55% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that CATX is not too dependend on debt financing.
CATX has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: CATX outperforms 46.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.91 |
ROIC/WACCN/A
WACC8.61%
2.3 Liquidity
CATX has a Current Ratio of 15.09. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
CATX has a Current ratio of 15.09. This is amongst the best in the industry. CATX outperforms 91.76% of its industry peers.
CATX has a Quick Ratio of 15.09. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 15.09, CATX belongs to the best of the industry, outperforming 91.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.09 | ||
| Quick Ratio | 15.09 |
3. Growth
3.1 Past
CATX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.45%, which is quite impressive.
CATX shows a small growth in Revenue. In the last year, the Revenue has grown by 1.39%.
CATX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -27.60% yearly.
EPS 1Y (TTM)22.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)1.39%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%-43.36%
3.2 Future
The Earnings Per Share is expected to decrease by -2.39% on average over the next years.
Based on estimates for the next years, CATX will show a very strong growth in Revenue. The Revenue will grow by 180.46% on average per year.
EPS Next Y-45.24%
EPS Next 2Y-26.16%
EPS Next 3Y-14.48%
EPS Next 5Y-2.39%
Revenue Next Year-15.71%
Revenue Next 2Y-19.37%
Revenue Next 3Y-27.37%
Revenue Next 5Y180.46%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CATX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CATX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CATX's earnings are expected to decrease with -14.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.16%
EPS Next 3Y-14.48%
5. Dividend
5.1 Amount
No dividends for CATX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.35
+0.12 (+5.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.73%
Inst Owner Change-1.48%
Ins Owners3.02%
Ins Owner Change0.01%
Market Cap174.70M
Revenue(TTM)1.45M
Net Income(TTM)-94.95M
Analysts82
Price Target13.41 (470.64%)
Short Float %10.93%
Short Ratio4.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.02%
Min EPS beat(2)5.8%
Max EPS beat(2)20.23%
EPS beat(4)4
Avg EPS beat(4)9.38%
Min EPS beat(4)3.49%
Max EPS beat(4)20.23%
EPS beat(8)7
Avg EPS beat(8)-7.99%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)108.21%
Min Revenue beat(2)84.07%
Max Revenue beat(2)132.36%
Revenue beat(4)3
Avg Revenue beat(4)61.84%
Min Revenue beat(4)-6.05%
Max Revenue beat(4)132.36%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.37%
PT rev (3m)-2.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.18%
EPS NY rev (1m)-1.18%
EPS NY rev (3m)-2.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.56%
Revenue NY rev (1m)2.29%
Revenue NY rev (3m)20.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 141.46 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.66 | ||
| P/tB | 0.81 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.14
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-1.55
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0.02
BVpS3.57
TBVpS2.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.56% | ||
| ROE | -35.74% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1763.14% | ||
| Cap/Sales | 4058.79% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 15.09 | ||
| Quick Ratio | 15.09 | ||
| Altman-Z | 0.91 |
F-Score1
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)856.63%
Cap/Depr(5y)587.66%
Cap/Sales(3y)1275.31%
Cap/Sales(5y)766.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y-45.24%
EPS Next 2Y-26.16%
EPS Next 3Y-14.48%
EPS Next 5Y-2.39%
Revenue 1Y (TTM)1.39%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%-43.36%
Revenue Next Year-15.71%
Revenue Next 2Y-19.37%
Revenue Next 3Y-27.37%
Revenue Next 5Y180.46%
EBIT growth 1Y-8.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.41%
EBIT Next 3Y-16.72%
EBIT Next 5YN/A
FCF growth 1Y-583.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-300.34%
OCF growth 3YN/A
OCF growth 5YN/A
PERSPECTIVE THERAPEUTICS INC / CATX FAQ
Can you provide the ChartMill fundamental rating for PERSPECTIVE THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to CATX.
What is the valuation status for CATX stock?
ChartMill assigns a valuation rating of 0 / 10 to PERSPECTIVE THERAPEUTICS INC (CATX). This can be considered as Overvalued.
How profitable is PERSPECTIVE THERAPEUTICS INC (CATX) stock?
PERSPECTIVE THERAPEUTICS INC (CATX) has a profitability rating of 1 / 10.
Can you provide the dividend sustainability for CATX stock?
The dividend rating of PERSPECTIVE THERAPEUTICS INC (CATX) is 0 / 10 and the dividend payout ratio is 0%.